Nature Aging study reports age-associated lipid acyl chain elongation constrains lifespan

Researchers identified that lipid acyl chains lengthen with age across species and that targeting the lipid-remodeling enzyme Plb1 extends lifespan in worms, highlighting lipid elongation as a novel therapeutic target.

A study published in Nature Aging by Li et al. demonstrated that lipid acyl chains systematically become longer during the aging process.

The researchers found that lipid elongation is highly conserved, occurring across multiple species, various tissues, and during the progression of heart disease.

To test the therapeutic potential of addressing this process, the researchers genetically targeted the lipid-remodeling enzyme Plb1 in Caenorhabditis elegans, which successfully extended the organisms' lifespan.

The study establishes lipid acyl chain length regulation as a conserved molecular mechanism influencing biological aging and cardiac disease progression.

By identifying Plb1 as a genetic node that regulates lipid length and lifespan, the research opens up a previously unexplored therapeutic target class focused on lipid-remodeling enzymes.

This discovery provides a novel target pathway for computational and target-discovery platforms aiming to address metabolic and cardiovascular aging.

Lipid acyl chain profiling could serve as a novel class of biomarkers for measuring biological age and monitoring the efficacy of longevity interventions in preclinical models.

Future studies evaluating whether targeting mammalian orthologs of Plb1 can replicate the lifespan-extending and cardioprotective effects in rodent models.